ClinicalTrials.gg
CompletedNCT05032859Updated Sep 2, 2025Results posted

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

A Phase 3 interventional study of tapinarof cream, 1% and vehicle cream in Atopic Dermatitis, sponsored by Organon and Co. Completed at 62 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.

Enrollment
3rd of 12
406 · median 168
Started
2021
with 3 others
Phase 3
5 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
5 of 12
Organon and Co

Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tapinarof in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.

Read the detailed description

This study is a 8-week double-blind, vehicle-controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 8 weeks. At the end of the 8-week study treatment, qualified subjects will have the option to enroll in an open-label, long-term extension study for an additional 48 weeks of treatment. Subjects who do not participate in the open-label, long-term extension study will complete a follow-up visit approximately one week after the end of treatment in this study.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • pediatric
  • tapinarof
  • phase 3
  • topical
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ages 2 and above with clinical diagnosis of AD
  • Subject with atopic dermatitis covering ≥5% and ≤ 35% of the BSA
  • A vIGA-AD score of ≥3 at screening and baseline
  • An EASI score of ≥6 at screening and baseline
  • Atopic dermatitis present for at least 6 months for ages 6 years old and above or 3 months for ages 2 to 5 years old
  • Female subjects of who are engaging in sexual activity that could lead to pregnancy should use acceptable methods
  • Must not be pregnant
  • Subject, subject's parent, or legal representative must be capable of giving written /assent

Exclusion criteria

Exclusion Criteria:

  • at screening
  • Chronic or acute systemic or superficial infection requiring treatment with systemic antibacterials or antifungals within one week prior to baseline visit
  • Significant dermatological or inflammatory condition other than AD that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
  • (ALT) or aspartate aminotransferase (AST) ≥2.0x the (ULN).
  • Screening total > 1.5x ULN
  • Current or chronic history of liver disease
  • Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
  • Subjects who would not be considered suitable for topical therapy
  • Use of any prohibited medication or procedure within the indicated period before the baseline visit including other product within 30 days or 5 half-lives of the investigational product (whichever is longer)
  • History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's participation in the study, interpretation of results, or ability to understand and give .
  • Pregnant or lactating females
  • History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the -Investigator or Medical Monitor, contraindicates their participation
  • Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    tapinarof cream

    tapinarof cream, 1%, applied topically once daily

    Drug: tapinarof cream, 1%

  • Placebo comparator
    vehicle cream

    vehicle cream, applied topically once daily

    Drug: vehicle cream

Interventions

  • applied topically once daily

  • Drugvehicle cream

    applied topically once daily

06

What researchers measure

Primary outcomes

  1. Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

    The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100 imputed datasets.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

    The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

    Time frame: Baseline to Week 8

  2. Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.

    Assessment of percent body surface area (%BSA) is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% \[10 handprints\], upper extremities = 20% \[20 handprints\], trunk (including axillae and groin) = 30% \[30 handprints\], lower extremities, including buttocks, = 40% \[40 handprints\]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

    Time frame: Baseline to Week 8

  3. Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

    The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

    Time frame: Baseline to Week 8

  4. Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.

    The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week. Statistics are based on 100 imputed datasets.

    Time frame: Baseline to Week 8

07

Results

Posted Sep 2, 2025

Participant flow

Participants from the main study (DMVT-505-3102) had the option to participate in the open label extension study (DMVT-505-3103, NCT05142774).

Participant flow — Overall Study
MilestoneTapinarof CreamVehicle Cream
Started271135
Completed235106
Not completed3629

Outcome measures

PrimaryPercent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100 imputed datasets.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of participants
Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
Percentage of participantsTapinarof CreamVehicle Cream
Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.46.418.0
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio, log: 2.27 · 95% CI 1.54 to 3.32Adjusted logit-based estimate of the common relative risk of success (Tapinarof Cream 1%/Vehicle Cream) over all strata. Multiple imputation p-value is for null hypothesis that the log (Relative Risk) equals 0.
SecondaryPercent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of participants
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
Percentage of participantsTapinarof CreamVehicle Cream
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.59.121.2
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio, log: 2.14 · 95% CI 1.53 to 3.00Adjusted logit-based estimate of the common relative risk of success (Tapinarof Cream 1%/Vehicle Cream) over all strata. Multiple imputation p-value is for null hypothesis that the log (Relative Risk) equals 0.
SecondaryMean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.

Assessment of percent body surface area (%BSA) is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% \[10 handprints\], upper extremities = 20% \[20 handprints\], trunk (including axillae and groin) = 30% \[30 handprints\], lower extremities, including buttocks, = 40% \[40 handprints\]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Time frame:
Baseline to Week 8
Reported as:
Mean · Change in affected BSA percentage
Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.
Change in affected BSA percentageTapinarof CreamVehicle Cream
Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.-10.36 ± 0.540-3.14 ± 0.676
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · ANCOVA · p = <0.0001 · Least squares mean difference: -6.60 · 95% CI -8.17 to -5.02age\*vIGA cohort and treatment as categorical covariates, and baseline %BSA as a continuous covariate
SecondaryPercent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of participants
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
Percentage of participantsTapinarof CreamVehicle Cream
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.30.110.0
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0013 · Risk ratio, log: 2.34 · 95% CI 1.39 to 3.94Adjusted logit-based estimate of the common relative risk of success (Tapinarof Cream 1%/Vehicle Cream) over all strata. Multiple imputation p-value is for null hypothesis that the log (Relative Risk) equals 0.
SecondaryPercent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.

The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week. Statistics are based on 100 imputed datasets.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of participants
Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.
Percentage of participantsTapinarof CreamVehicle Cream
Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.52.824.1
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0015 · Risk ratio, log: 2.17 · 95% CI 1.34 to 3.50Adjusted logit-based estimate of the common relative risk of success (Tapinarof Cream 1%/Vehicle Cream) over all strata. Multiple imputation p-value is for null hypothesis that the log (Relative Risk) equals 0.

Adverse events

Collected over Through study completion, up to 9 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tapinarof Cream0/271 (0%)2/271 (0.7%)55/271 (20.3%)
Vehicle Cream0/133 (0%)0/133 (0%)13/133 (9.8%)
Most frequent serious events
Most frequent serious events
EventTapinarof CreamVehicle Cream
Colitis ischaemicGastrointestinal disorders1/2710/133
Psychogenic seizureNervous system disorders1/2710/133
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTapinarof CreamVehicle Cream
FolliculitisInfections and infestations22/2712/133
Upper respiratory tract infectionInfections and infestations8/2712/133
COVID-19Infections and infestations6/2710/133
PyrexiaGastrointestinal disorders4/2712/133
Dermatitis contactSkin and subcutaneous tissue disorders3/2712/133
EczemaSkin and subcutaneous tissue disorders1/2712/133
Dermatitis atopicSkin and subcutaneous tissue disorders0/2712/133
NasopharyngitisInfections and infestations4/2711/133
HeadacheNervous system disorders4/2710/133
AsthmaRespiratory, thoracic and mediastinal disorders4/2710/133

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(years)Tapinarof CreamVehicle CreamTotal
Mean16.4 ± 16.2416.7 ± 16.0516.5 ± 16.16
Age, Customized
Age, Customized(Participants)Tapinarof CreamVehicle CreamTotal
2-6 Years653297
7-11 Years643296
12-17 Years8944133
≥18 Years532780
Sex: Female, Male
Sex: Female, Male(Participants)Tapinarof CreamVehicle CreamTotal
Female15477231
Male11758175
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tapinarof CreamVehicle CreamTotal
Hispanic or Latino492776
Not Hispanic or Latino221107328
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tapinarof CreamVehicle CreamTotal
American Indian or Alaska Native022
Asian392362
Native Hawaiian or Other Pacific Islander101
Black or African American9547142
White12458182
More than one race628
Unknown or Not Reported639
Region of Enrollment
Region of Enrollment(Count of participants)Tapinarof CreamVehicle CreamTotal
Canada412263
United States230113343
Validated Investigator Global Assessment for Atopic Dermatitis
Validated Investigator Global Assessment for Atopic Dermatitis(Participants)Tapinarof CreamVehicle CreamTotal
0 - Clear000
1 - Almost Clear000
2 - Mild000
3 - Moderate228113341
4 - Severe432265
Percent Body Surface Area (BSA)
Percent Body Surface Area (BSA)(Percentage of Affected BSA)Tapinarof CreamVehicle CreamTotal
Mean17.13 ± 8.74315.84 ± 7.88816.70 ± 8.480

1 further baseline measures are reported on the registry.

08

Study locations

62 sites
  • Dermavant Investigative Site
    Birmingham, Alabama 35244, United States
  • Dermavant Investigative Site
    Scottsdale, Arizona 85255, United States
  • Dermavant Investigative Site
    Scottsdale, Arizona 85260, United States
  • Dermavant Investigative Site
    Fort Smith, Arkansas 72916, United States
  • Dermavant Investigative Site
    Cerritos, California 90702, United States
  • Dermavant Investigative Site
    Huntington Beach, California 92647, United States
  • Dermavant Investigative Site
    Lancaster, California 93534, United States
  • Dermavant Investigative Site
    Long Beach, California 90806, United States
  • Dermavant Investigative Site
    Los Angeles, California 90045, United States
  • Dermavant Investigative Site
    San Diego, California 92123, United States
  • Dermavant Investigative Site
    San Francisco, California 94115, United States
  • Dermavant Investigative Site
    Santa Ana, California 92701, United States
  • Dermavant Investigative Site
    Santa Monica, California 90404, United States
  • Dermavant Investigative Site
    Boca Raton, Florida 33428, United States
  • Dermavant Investigative Site
    Delray Beach, Florida 33484, United States
  • Dermavant Investigative Site
    Jacksonville, Florida 32256, United States
  • Dermavant Investigative Site
    Miami, Florida 33165, United States
  • Dermavant Investigative Site
    Miami, Florida 33173, United States
  • Dermavant Investigative Site
    Miami Lakes, Florida 33014, United States
  • Dermavant Investigative Site
    Tampa, Florida 33607, United States
  • Dermavant Investigative Site
    Snellville, Georgia 30078, United States
  • Dermavant Investigative Site
    Evansville, Indiana 47715, United States
  • Dermavant Investigative Site
    Overland Park, Kansas 66210, United States
  • Dermavant Investigative Site
    Lexington, Kentucky 40517, United States
  • Dermavant Investigative Site
    Louisville, Kentucky 40241, United States
  • Dermavant Investigative Site
    Baton Rouge, Louisiana 70808, United States
  • Dermavant Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Dermavant Investigative Site
    New Orleans, Louisiana 70115, United States
  • Dermavant Investigative Site
    Rockville, Maryland 20850, United States
  • Dermavant Investigative Site
    Detroit, Michigan 48202, United States
  • Dermavant Investigative Site
    Lincoln, Nebraska 68516, United States
  • Dermavant Investigative Site
    Omaha, Nebraska 68114, United States
  • Dermavant Investigative Site
    Las Vegas, Nevada 89148, United States
  • Dermavant Investigative Site
    East Windsor, New Jersey 08520, United States
  • Dermanvant Investigative Site
    Brooklyn, New York 11203, United States
  • Dermavant Investigative Site
    Watertown, New York 13601, United States
  • Dermavant Investigative Site
    Charlotte, North Carolina 28277, United States
  • Dermavant Investigative Site
    Dayton, Ohio 45414, United States
  • Dermavant Investigative Site
    Mason, Ohio 45040, United States
  • Dermavant Investigative Site
    Mayfield Heights, Ohio 44124, United States
  • Dermavant Investigative Site
    Tulsa, Oklahoma 74114, United States
  • Dermavant Investigative Site
    Medford, Oregon 97504, United States
  • Dermavant Investigative Site
    Portland, Oregon 97210, United States
  • Dermavant Investigative Site
    Portland, Oregon 97239, United States
  • Dermavant Investigative Site
    East Greenwich, Rhode Island 02818, United States
  • Dermavant Investigative Site
    Anderson, South Carolina 29621, United States
  • Dermavant Investigative Site
    North Charleston, South Carolina 29420, United States
  • Dermavant Investigative Site
    Spartanburg, South Carolina 29303, United States
  • Dermavant Investigative Site
    Memphis, Tennessee 38119, United States
  • Dermavant Investigative Site
    Bellaire, Texas 77401, United States
  • Dermavant Investigative Site
    Dripping Springs, Texas 78620, United States
  • Dermavant Investigative Site
    Grapevine, Texas 76051, United States
  • Dermavant Investigative Site
    Houston, Texas 77004, United States
  • Dermavant Investigative Site
    Houston, Texas 77061, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78213, United States
  • Dermavant Investigative Site
    Webster, Texas 77598, United States
  • Dermavant Investigative Site
    Spokane, Washington 99202, United States
  • Dermavant Investigative Site
    Surrey, British Columbia V3R 6A7, Canada
  • Dermavant Investigative Site
    Barrie, Ontario L4M 7G1, Canada
  • Dermavant Investigative Site
    Markham, Ontario L3P 1X3, Canada
  • Dermavant Investigative Site
    Waterloo, Ontario N2J 1C4, Canada
  • Dermavant Investigative Site
    Windsor, Ontario N8W 1E6, Canada
09

References and documents

Publications

  • Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Papp KA, Browning J, Kwong P, Korman NJ, Brown PM, Rubenstein DS, Piscitelli SC, Somerville MC, Tallman AM, Kircik L. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024 Sep;91(3):457-465. doi: 10.1016/j.jaad.2024.05.023. Epub 2024 May 20. PubMed 38777187 ↗
  • Alexis AF, Kircik L, Chovatiya R, Rice ZP, Soong W, Bhutani T, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials. Dermatol Ther (Heidelb). 2025 Sep;15(9):2667-2682. doi: 10.1007/s13555-025-01489-w. Epub 2025 Jul 22. PubMed 40696240 ↗
  • Gold LS, Bruno MJ, Lewitt GM, Hebert AA. Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis. J Dermatolog Treat. 2025 Dec;36(1):2517388. doi: 10.1080/09546634.2025.2517388. Epub 2025 Jul 2. PubMed 40600584 ↗
  • Bissonnette R, Stein Gold L, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. J Am Acad Dermatol. 2025 Sep;93(3):707-714. doi: 10.1016/j.jaad.2025.05.1391. Epub 2025 May 16. PubMed 40383273 ↗
  • Gold LS, Del Rosso J, Ehst BD, Zirwas MJ, Green LJ, Brown PM, Rubenstein DS, Piscitelli SC, Tallman AM. Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials. J Dermatolog Treat. 2025 Dec;36(1):2444489. doi: 10.1080/09546634.2024.2444489. Epub 2025 Jan 12. PubMed 39799945 ↗
  • Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children. Dermatol Ther (Heidelb). 2025 Jan;15(1):111-124. doi: 10.1007/s13555-024-01318-6. Epub 2025 Jan 7. PubMed 39777610 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Feb 2023, 16 months.

Results were first posted in Sep 2025, 2 years 6 months after primary completion. A results delay was requested in Mar 2023.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 16 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 2, 2021
StartActual
Sep 23, 2021
Primary completionActual
Feb 3, 2023
CompletionActual
Feb 8, 2023
Results delay requested
Mar 23, 2023
Results first posted
Sep 2, 2025
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05032859
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Sep 23, 2021
Primary completion
Feb 3, 2023
Completion
Feb 8, 2023
Results posted
Sep 2, 2025
Last update
Sep 2, 2025

Study contacts

Diana Villalobos
study director · Dermavant Sciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion